Avid Bioservices, Inc.

CDMO

US05368M1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
8.67 ^USD	+6.51%		+5.09%	+33.38%

Apr. 30	RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	MT
Apr. 29	Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024

Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

March 08, 2022 at 04:09 pm EST

Avid Bioservices, Inc. reiterating revenue guidance for the fiscal year 2022. The company is reiterating revenue guidance for fiscal 2022 of $115 million to $117 million, a 20% to 22% increase over fiscal 2021.

Latest news about Avid Bioservices, Inc.

RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating	Apr. 30	MT
Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024	Apr. 29
Avid Bioservices, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Apr. 24	CI
North American Morning Briefing : Stock Futures -2-	Apr. 19	DJ
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice	Mar. 20	MT
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating	Mar. 11	MT
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump	Mar. 07	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments	Mar. 07	MT
Top Premarket Decliners	Mar. 07	MT
Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes	Mar. 07	DJ
Avid Bioservices Prices $160 Million Convertible Notes Offering	Mar. 07	MT
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump	Mar. 06	MT
Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024	Mar. 06	CI
Avid Bioservices, Inc. announced that it expects to receive $160 million in funding	Mar. 05	CI
In moon race with China, U.S. setbacks test role of private firms	Jan. 12	RE
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 1000	Dec. 18	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600 Health Care	Dec. 18	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Composite 1500	Dec. 18	CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600	Dec. 18	CI
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating	Dec. 08	MT
Avid Bioservices Faces Uphill Battle as Overall Demand Environment Poses Challenges, RBC Says	Dec. 08	MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating	Dec. 08	MT

Chart Avid Bioservices, Inc.

Duration

Period

More charts

Company Profile

Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Companyâs services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.

Sector

Pharmaceuticals

Calendar

2024-05-14 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Avid Bioservices, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.67 USD

Average target price

12.5 USD

Spread / Average Target

+44.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AVID BIOSERVICES, INC.	+33.38%	550M
CSL LIMITED	-2.61%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+3.55%	40.9B
BIOGEN INC.	-14.40%	32.25B
UCB	+55.89%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-15.96%	15.39B
INCYTE CORPORATION	-15.50%	11.91B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.29%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.75%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.87%	9.03B

Biopharmaceuticals